Table 1 Clinical background of study population
Control | iNPH | P value | |
|---|---|---|---|
Number | 9 | 20 | |
Male preponderance, N (%) | 6 (66.7) | 12 (60) | 0.7308 |
Age | 74.2 ± 7.9 | 76.1 ± 6.4 | 0.6869 |
History | |||
Hypertension | 5 | 11 | 0.9778 |
Diabetes mellitus | 0 | 2 | 0.2128 |
Hyperlipidemia | 3 | 6 | 0.858 |
Anti-coagulant/platelet drugs | 1 | 8 | 0.0988 |
Lacunar stroke | 1 | 2 | 0.928 |
Alzheimer’s disease | 0 | 3 | 0.1417 |
Chronic kidney disease | 0 | 1 | 0.0713 |
Chronic obstructive pulmonary disease | 0 | 1 | 0.0713 |
Activity of daily life | |||
Modified Rankin scale (G2, 3, 4)/(G0–4) (%) | 0 | 95 | <0.0001* |
Symptoms (iNPHGS) | |||
Gait disturbance (G2–4)/(G0–4) (%) | 0 | 85 | <0.0001* |
Cognition disturbance (G2–4)/(G0–4) (%) | 0 | 85 | <0.0001* |
Urination disturbance (G2–4)/(G0–4) (%) | 0 | 75 | 0.0009* |
Tap test | |||
TUG (baseline) (s) | NA | 35.0 ± 47.7 | |
TUG (% change) | NA | 25.6 ± 34.6 | |
MMSE (baseline score) | NA | 21.4 ± 5.9 | |
MMSE (difference) | NA | 3.1 ± 2.9 | |
Shunt surgery, N | 0 | 12 | |